| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e4f0548ee4ecf77e552c58c637d6aa11 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-346
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-11
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-3231 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-7105
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70503
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1136
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7088
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 |
| filingDate |
2020-05-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e745a2e80edc631ad17d74180ce2d80a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fcf5ef8099858c766bd47ae3d3ca82b1
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_11833b56083b7e958d0b8c39681378fc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea09beda2371f9fbc3bdaa1b2b5d3c6f |
| publicationDate |
2022-01-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
KR-20220005045-A |
| titleOfInvention |
PD-L1 antisense oligonucleotides for use in tumor therapy |
| abstract |
The present invention is an oligonucleotide consisting of 10 to 20 nucleotides that hybridizes with SEQ ID NO: 1 encoding PD-L1, wherein the number of potential off-target binding sites is fundamentally reduced, thereby greatly reducing the risk of off-target effects. It relates to oligonucleotides. The present invention also relates to a pharmaceutical composition comprising such an oligonucleotide and a pharmaceutically acceptable excipient. |
| priorityDate |
2019-05-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |